JavaScript not supported in your browser. Some content might be hidden.Theramex: Building a dedicated platform for women’s health | CVC

Millions of women around the world live better lives with the help of Theramex, a leading global specialty pharmaceuticals company dedicated to women and their health, offering patient-focused solutions, education and support across contraception, fertility, menopause and osteoporosis.

Key information

Region United Kingdom
Sector Healthcare
Strategy Europe/Americas
Theramex website

Building a dedicated platform for women's health

Building a dedicated platform for women's health

Theramex empowers women to make informed decisions about managing the cycles and stages of their life, providing products that can support them through their life journey. The company operates in over 80 countries across EMEA, APAC and South America.

In 2018, CVC acquired a portfolio of women’s health pharma products from Teva Pharmaceutical Industries Ltd. CVC saw an opportunity to create a new business dedicated to women's health. Within three years, the enterprise delivered double-digit revenue and EBITDA growth through a transformation strategy.

  • A new leadership team and full operational resources were established to accelerate a previously undermanaged set of products and scale the portfolio further.
  • The go-to-market strategy was transformed, building on loyal relationships with physicians through a dedicated sales force, along with a strengthened supply chain network.
  • Digital tools were enhanced to support and serve clinicians better.
  • A successful M&A agenda was delivered, with 15 acquisitions completed to grow the platform and bring new products to market.

Together, we have built one of the world's largest pharmaceutical companies dedicated solely to women's health, improving lives and ensuring these important products are made available to all who need them.

Robert Stewart CEO, Theramex

Well-positioned for the next growth phase

Theramex is now at the forefront of raising awareness and delivering better, more effective therapies for women across the globe, particularly in relation to menopause, endometriosis and osteoporosis.

In March 2022, it was announced that global investment firms PAI Partners and Carlyle had agreed to acquire Theramex from CVC . Under new ownership, Theramex is looking to expand its product suite in existing and adjacent therapeutic areas and accelerate its international growth and thanks to the strong foundations laid over recent years the business is perfectly positioned to continue to thrive.